# A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease.

> **NCT06185543** · PHASE2 · TERMINATED · sponsor: **NeuroSense Therapeutics Ltd.** · enrollment: 8 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** PrimeC
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06185543
- **Lead sponsor:** NeuroSense Therapeutics Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-11-19
- **Primary completion:** 2025-09-30
- **Final completion:** 2025-09-30
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Company will improve study desig
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06185543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06185543, "A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06185543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*